Abstract
AbstractBackgroundIn clinical trials and other disease research, biomarkers provide a valuable indication of drug performance and disease progression. Traditionally, these biomarkers may include genomic factors, lab test results, and more, but we now can easily expand into longitudinally collected digital biomarkers from consumer smart devices.MethodThe Amissa platform, built on the Microsoft Azure cloud, enables the collection of high frequency data from consumer smartwatches (such as the Apple Watch and Samsung Galaxy watch devices). The API‐driven cloud architecture enables secure sensor data collection including location, gyrometry/accelerometry, activity monitoring/pedometry, and biosensors such as oxygen saturation and heart rate. This solution allows for sub‐minute capture frequency while balancing device battery drain. The ISO 27001:2013‐compliant platform is globally scalable through an innovative cloud‐native design that ensures security and compliance.ResultCaregivers, researchers, and healthcare providers can now monitor loved ones/patients through consumer‐grade wearables, providing a cost‐effective, accurate, and flexible solution for biomarker discovery, data collection, and remote monitoring.ConclusionThe Amissa platform successfully enables digital biomarker development and helps to address disparities in clinical trials and research studies of underrepresented groups through decentralized data collection. Plus, the platform address security and privacy considerations while enables collaborative research participation and flexible study designs. Note: In this presentation, we will discuss the NIH‐funded work of Amissa and the cloud‐first approach taken to build the world’s first global‐scale platform for disease research using wearable devices. We will cover technical design patterns, considerations for privacy and security, the effect of decentralized data collection on addressing health disparities and inclusion in clinical trials, and the future of digital biomarker discovery in Alzheimer’s disease and related dementias.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
